000			01893nam a2200397 i 4500
999			_c257417 _d257417
001			ocn968934049
003			BD
005			20171226113934.0
006			m o d f
007			cr bn||||a||||
008			170118s2016 dcu ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dMvI
042			_apcc
043			_an-us---
049			_aBDDF
050	1	4	_aKF27 _b.E5546 2016
074			_a1019-B-01 (MF)
086	0		_aY 4.C 73/8:114-173
088			_aSerial no. 114-173 (United States. Congress. House. Committee on Energy and Commerce)
099			_aY 4.C 73/8:114-173
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce. _bSubcommittee on Oversight and Investigations, _eauthor.
245	1	0	_aBioresearch labs and inactivation of dangerous pathogens : _bhearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Fourteenth Congress, second session, September 27, 2016.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2016.
337			_amicroform _bh _2rdamedia
338			_amicrofiche _bhe _2rdacarrier
500			_aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.
500			_a"Serial No. 114-173."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource, PDF version; title from title page (FDsys web site, viewed on Jan. 18, 2017).
650		0	_aPathogenic microorganisms _xHandling _zUnited States _xSafety measures.
650		0	_aMicrobial inactivation _xSafety measures.
650		0	_aBiological laboratories _zUnited States _xSafety measures.
655		7	_aLegislative hearings. _2lcgft
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo76669
942			_2sudocs _c12